Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Wilmott

Showing results (21-30 of 162) with videos related to

Pageof 17
Sort By:
ESMO Open|June 21, 2025
Do BRAF-targeted therapies have a role in the era of immunotherapy?J Braden, J W Conway, J S Wilmott, et al.
Frontiers in Immunology|December 5, 2022
The effect of organ-specific tumor microenvironments on response patterns to immunotherapyJordan W Conway, Jorja Braden, James S Wilmott, et al.
Frontiers in Oncology|October 24, 2022
Causes, consequences and clinical significance of aneuploidy across melanoma subtypesEva R Shteinman, James S Wilmott, Ines Pires da Silva, et al.
IEEE Journal of Biomedical and Health Informatics|November 24, 2025
Deep Learning Framework for Classifying Whole-Slide Multiplex Immunofluorescence Images to Predict Immunotherapy Response in Melanoma PatientsPriyanka Rana, Tuba N Gide, Nurudeen A Adegoke, et al.
International Journal of Molecular Sciences|April 23, 2022
Expression of NGF/proNGF and Their Receptors TrkA, p75<sup>NTR</sup> and Sortilin in MelanomaMark Marsland, Amiee Dowdell, Chen Chen Jiang, et al.
Pathology|March 6, 2022
Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanomaAndrew J Colebatch, Elizabeth C Paver, Ismael A Vergara, et al.
Pathology|December 1, 2018
Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 casesTristan J Dodds, James S Wilmott, Louise A Jackett, et al.
Frontiers in Oncology|June 13, 2020
Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF InhibitorsArturas Ziemys, Michelle Kim, Alexander M Menzies, et al.
Annals of Surgical Oncology|October 29, 2017
Reply to comment on: Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (< 0.1 mm) Sentinel Lymph Node MetastasesLodewijka H J Holtkamp, Shu Wang, James S Wilmott, et al.
Pathology|September 11, 2013
BAP1 expression in cutaneous melanoma: a pilot studyRajmohan Murali, James S Wilmott, Valerie Jakrot, et al.
Pageof 17

Showing results (21-30 of 162) with videos related to

Sort By:
Pageof 17
ESMO Open|June 21, 2025
Do BRAF-targeted therapies have a role in the era of immunotherapy?J Braden, J W Conway, J S Wilmott, et al.
Frontiers in Immunology|December 5, 2022
The effect of organ-specific tumor microenvironments on response patterns to immunotherapyJordan W Conway, Jorja Braden, James S Wilmott, et al.
Frontiers in Oncology|October 24, 2022
Causes, consequences and clinical significance of aneuploidy across melanoma subtypesEva R Shteinman, James S Wilmott, Ines Pires da Silva, et al.
IEEE Journal of Biomedical and Health Informatics|November 24, 2025
Deep Learning Framework for Classifying Whole-Slide Multiplex Immunofluorescence Images to Predict Immunotherapy Response in Melanoma PatientsPriyanka Rana, Tuba N Gide, Nurudeen A Adegoke, et al.
International Journal of Molecular Sciences|April 23, 2022
Expression of NGF/proNGF and Their Receptors TrkA, p75<sup>NTR</sup> and Sortilin in MelanomaMark Marsland, Amiee Dowdell, Chen Chen Jiang, et al.
Pathology|March 6, 2022
Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanomaAndrew J Colebatch, Elizabeth C Paver, Ismael A Vergara, et al.
Pathology|December 1, 2018
Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 casesTristan J Dodds, James S Wilmott, Louise A Jackett, et al.
Frontiers in Oncology|June 13, 2020
Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF InhibitorsArturas Ziemys, Michelle Kim, Alexander M Menzies, et al.
Annals of Surgical Oncology|October 29, 2017
Reply to comment on: Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (< 0.1 mm) Sentinel Lymph Node MetastasesLodewijka H J Holtkamp, Shu Wang, James S Wilmott, et al.
Pathology|September 11, 2013
BAP1 expression in cutaneous melanoma: a pilot studyRajmohan Murali, James S Wilmott, Valerie Jakrot, et al.
Pageof 17